Biological
KSVCBD injection
KSVCBD injection is a biological therapy with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
2
50%
Ph early_phase_1
2
50%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 1Safety & dosage
2(50.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting2
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 12 (50.0%)
Phase 12 (50.0%)
Trials by Status
recruiting250%
not_yet_recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
NCT07620314
recruitingphase_1
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
NCT07620275
not_yet_recruitingearly_phase_1
Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases
NCT07613411
not_yet_recruitingearly_phase_1
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
NCT07592754
Clinical Trials (4)
Showing 4 of 4 trials
NCT07620314Phase 1
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
NCT07620275Phase 1
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
NCT07613411Early Phase 1
Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases
NCT07592754Early Phase 1
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4